Government spends billions on ARVs

Spokesperson for the department, Sibani Mngadi said that most of the drugs cost less than the last tender with percentage decreases ranging between 20 and 71 percent. The only drug which increased in price(by 24%) was efavirenz 200mg.

Mngadi attributed the reduction in price to the ‘€œhigher volumes and generic entry and a more competitive climate’€.

Aspen Pharmacare was the biggest winner with 56,8% of the R3,615-billion tender awarded to the generic manufacturer. The awards varied from 1,9% to 56.8% of the total value, spread over six suppliers.

GlaxoSmithKline was awarded 6,9% of the tender, Adcock Ingram 20,9%, MSD 9,1%, Medpro 1,9% and Sonke 4,5%.

Mngadi said six items had not been awarded and arrangements for their procurement would soon be made.

‘€œThe awarding of this tender once again demonstrates the continued commitment of the Department of Health to expanding access to HIV and AIDS related treatment. ‘€œWe have to ensure that there is adequate and uninterrupted supply of the necessary medicine to the accredited treatment centres across the country,’€ said Mngadi.

He claimed that the South African government ARV tender was the largest in the world and that the accumulative number of patients initiated on ARVs was more than 478 000 by the end of April 2008. ‘€“ health-e news service

Author

  • Health-e News

    Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews

    View all posts

Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


Related

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay in the loop

We see you enjoy reading our articles, subscribe now and receive our articles in your inbox.

Newsletter Subscription

Enable Notifications